BioForce Nanosciences (BFNH) Stock Price, News & Analysis

Company Overview

BioForce Nanosciences, Inc. develops nanotechnology tools and systems designed for research in life sciences, materials science and related fields. The company’s technologies are intended to support the controlled manipulation, deposition and analysis of very small quantities of biological and chemical materials.

Its product portfolio has included nanoscale patterning and fluid-handling systems, including the Nano eNabler platform. These tools are designed for applications such as creating biological arrays, depositing samples and reagents, and conducting research involving cells, proteins, DNA and other materials at the micro- and nanoscale.

BioForce Nanosciences was based in the United States and focused primarily on serving scientific, academic and industrial research markets. Publicly available information about its current operations, geographic reach and leadership is limited.

Key Stats

• Today's Range: $6.60 to $8.96
• 50-Day Range: $1.84 to $10.01
• 52-Week Range: $0.18 to $10.99
• Volume: 5,230 shs
• Average Volume: 12,230 shs
• Market Capitalization: $312.14 million
• P/E Ratio: 820.82
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BioForce Nanosciences Stock Analysis - MarketRank™

BioForce Nanosciences scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for BioForce Nanosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of BioForce Nanosciences is 820.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioForce Nanosciences is 820.82, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.36.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of BioForce Nanosciences has been sold short.

Short Interest Ratio / Days to Cover

BioForce Nanosciences has a short interest ratio ("days to cover") of 0.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioForce Nanosciences has recently decreased by 67.25%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioForce Nanosciences does not currently pay a dividend.

Dividend Growth

BioForce Nanosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.38

News Sentiment

BioForce Nanosciences has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for BioForce Nanosciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioForce Nanosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.54% of the stock of BioForce Nanosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioForce Nanosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BFNH
• CIK: 1310488
• Web: www.bioforceeclipse.com
• Phone: (757) 306-6090
• Fax: 757-306-6092
• Employees: 3
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): $0.01
• Trailing P/E Ratio: 820.82
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.67%
• Return on Assets: -16.36%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.41
• Quick Ratio: 25.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.02) per share
• Price / Book: -410.00

Miscellaneous

• Outstanding Shares: 38,066,000
• Free Float: 23,015,000
• Market Cap: $312.14 million
• Optionable: Not Optionable
• Beta: 0.63